Logo image of GLPG.AS

GALAPAGOS NV (GLPG.AS) Stock Overview

AMS:GLPG - BE0003818359 - Common Stock

26.94 EUR
-1.2 (-4.26%)
Last: 8/29/2025, 7:00:00 PM

GLPG.AS Key Statistics, Chart & Performance

Key Statistics
52 Week High31.08
52 Week Low20
Market Cap1.78B
Shares65.90M
Float49.19M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-4.32
PEN/A
Fwd PEN/A
Earnings (Next)10-22 2025-10-22
IPO05-06 2005-05-06
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


GLPG.AS short term performance overview.The bars show the price performance of GLPG.AS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 4 -4 6

GLPG.AS long term performance overview.The bars show the price performance of GLPG.AS in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -10 -20 -30 -40

The current stock price of GLPG.AS is 26.94 EUR. In the past month the price decreased by -4.06%. In the past year, price increased by 2.12%.

GALAPAGOS NV / GLPG Daily stock chart

GLPG.AS Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 19.74 316.57B
1ABBV.MI ABBVIE INC 19.14 314.07B
AMG.DE AMGEN INC 13.1 131.93B
1GILD.MI GILEAD SCIENCES INC 14.46 122.10B
GIS.DE GILEAD SCIENCES INC 14.49 119.42B
VX1.DE VERTEX PHARMACEUTICALS INC 23.06 85.89B
ARGX.BR ARGENX SE 81.51 36.96B
22UA.DE BIONTECH SE-ADR N/A 20.70B
IDP.DE BIOGEN INC 8.27 16.64B
1MRNA.MI MODERNA INC N/A 8.13B
0QF.DE MODERNA INC N/A 7.95B
1EXAS.MI EXACT SCIENCES CORP N/A 7.52B

About GLPG.AS

Company Profile

GLPG logo image Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 558 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.

Company Info

GALAPAGOS NV

Generaal De Wittelaan L11 A3

MALINES (MECHELEN) ANTWERPEN BE

Employees: 558

GLPG Company Website

GLPG Investor Relations

Phone: 3215342900

GALAPAGOS NV / GLPG.AS FAQ

What is the stock price of GALAPAGOS NV today?

The current stock price of GLPG.AS is 26.94 EUR. The price decreased by -4.26% in the last trading session.


What is the ticker symbol for GALAPAGOS NV stock?

The exchange symbol of GALAPAGOS NV is GLPG and it is listed on the Euronext Amsterdam exchange.


On which exchange is GLPG.AS stock listed?

GLPG.AS stock is listed on the Euronext Amsterdam exchange.


What is the price forecast or stock price prediction for GALAPAGOS NV stock?

17 analysts have analysed GLPG.AS and the average price target is 29.5 EUR. This implies a price increase of 9.5% is expected in the next year compared to the current price of 26.94. Check the GALAPAGOS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GALAPAGOS NV worth?

GALAPAGOS NV (GLPG.AS) has a market capitalization of 1.78B EUR. This makes GLPG.AS a Small Cap stock.


How many employees does GALAPAGOS NV have?

GALAPAGOS NV (GLPG.AS) currently has 558 employees.


What are the support and resistance levels for GALAPAGOS NV (GLPG.AS) stock?

GALAPAGOS NV (GLPG.AS) has a support level at 26.93 and a resistance level at 27.61. Check the full technical report for a detailed analysis of GLPG.AS support and resistance levels.


Is GALAPAGOS NV (GLPG.AS) expected to grow?

The Revenue of GALAPAGOS NV (GLPG.AS) is expected to decline by -7.45% in the next year. Check the estimates tab for more information on the GLPG.AS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GALAPAGOS NV (GLPG.AS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GALAPAGOS NV (GLPG.AS) stock pay dividends?

GLPG.AS does not pay a dividend.


When does GALAPAGOS NV (GLPG.AS) report earnings?

GALAPAGOS NV (GLPG.AS) will report earnings on 2025-10-22.


What is the Price/Earnings (PE) ratio of GALAPAGOS NV (GLPG.AS)?

GALAPAGOS NV (GLPG.AS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.32).


GLPG.AS Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to GLPG.AS. When comparing the yearly performance of all stocks, GLPG.AS turns out to be only a medium performer in the overall market: it outperformed 47.5% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

GLPG.AS Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to GLPG.AS. The financial health of GLPG.AS is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GLPG.AS Financial Highlights

Over the last trailing twelve months GLPG.AS reported a non-GAAP Earnings per Share(EPS) of -4.32. The EPS decreased by -200.7% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -7.45%
ROE -10.75%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-1242.86%
Sales Q2Q%-16.16%
EPS 1Y (TTM)-200.7%
Revenue 1Y (TTM)-52.5%

GLPG.AS Forecast & Estimates

17 analysts have analysed GLPG.AS and the average price target is 29.5 EUR. This implies a price increase of 9.5% is expected in the next year compared to the current price of 26.94.

For the next year, analysts expect an EPS growth of -346.2% and a revenue growth -7.45% for GLPG.AS


Analysts
Analysts49.41
Price Target29.5 (9.5%)
EPS Next Y-346.2%
Revenue Next Year-7.45%

GLPG.AS Ownership

Ownership
Inst Owners49.75%
Ins Owners0%
Short Float %N/A
Short RatioN/A